Truist raised the firm’s price target on Intuitive Surgical to $520 from $515 and keeps a Buy rating on the shares. The analyst cites the company’s “solid” Q2 revenue and earnings beat, headlined by procedure and system upside with higher than expected placement of dV5’s. Intuitive Surgical remains a preferred large cap on the firm’s expectations that it can sustain a mid-to-high teens revenue and earnings CAGR, Truist tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- ISRG Earnings: Intuitive Surgical Gains after Q2 Earnings Beat
- Options Volatility and Implied Earnings Moves Today, July 18, 2024
- Intuitive Surgical price target raised to $490 from $430 at Barclays
- Intuitive Surgical price target raised to $515 from $450 at Truist
- ISRG Earnings this Week: How Will it Perform?